Market Research Report : Coronary stents market in india 2014 - Sample

Insert Cover Image using Slide Master View
Do not distort
Coronary Stents Market – India
August 2014

2
Executive Summary
Market
Drivers & Challenges
Competitive Landscape
Coronary stents market in India is expected to grow at a CAGR of x1% and x2% in value-terms and volume-terms respectively, over 2012 - 2018e
There are three types of coronary stents available in the market, bare metal stents (BMS), drug- eluting stents (DES), and bioabsorbable stents
Drivers:
Increasing lifestyle based diseases
Improving health infrastructure
Changing demographics
Increased healthcare spending and insurance coverage
Advancements in technology and medical procedures
Challenges:
Problems associated with usage
Constant need for innovation and new product development
Major Foreign Companies
Major Domestic Companies
Company 1
Company 2
Company 3
Company 4
Company 5
Company 6
Buyer Details
Top Hospitals Buying Coronary Stents in India
Hospital 1
Hospital 2
Hospital 3
Hospital 4
Hospital 5
Hospital 6
Regulatory Bodies
Regulatory Policies
Regulatory Processes
Government Involvement
CORONARY STENTS MARKET IN INDIA 2014.PPT

3
•Macroeconomic Indicators
•Introduction
•Market Overview
•Drivers & Challenges
•Government Involvement
Regulatory Bodies
Regulatory Policies
Regulatory Processes
•Competitive Landscape
•Buyer Details
•Recent Developments
•Strategic Recommendations
•Appendix

4
Economic Indicators (1/3)
11
12
13
14
15
INR tn
Q4
c4
b4
a4
Q3
c3
b3
a3
Q2
d2
c2
b2
a2
Q1
d1
c1
b1
a1
2010-11 2011-12 2012-13 2013-14
GDP at Factor Cost: Quarterly
Inflation Rate: Monthly
-2
-1
0
1
2
%
Sep 2013 - Oct 2013
p
-t
Jul 2013 - Aug 2013 Aug 2013 - Sep 2013 Oct 2013 - Nov 2013
q
r
Nov 2013 - Dec 2013
s

5
Market Size and Growth (Value-Wise)
Coronary Stents Market – Overview
• Indian market for coronary stents is expected to show steady growth in coming years, providing strong
opportunities for potential players to earn high revenues and increase their profits
• There are three types of coronary stents available in the market, bare metal stents, drug-eluting stents and
bioabsorbable stents
• Type 1 stents experience the highest demand while Type 2 stents are still at a nascent stage
Indian market for coronary stents is poised to grow in the
coming years with emphasis on drug-eluting stents
Market Size and Growth (Volume-Wise)
0
10
20
30
40
50
g3%
g2%
g1%
2016e
b1%
2012
a
a2%
a1%
d3%
d2%
d1%
2014e
c
c3%
f
f3%
f2%
f1%
2015e
d
2017e
g
c2%
c1%
2013
b
b3% b2%
INR bn
x1%
2018e
h
h3%
h2%
h1%
Type 1 Type 2 Type 3
0
200
400
600
800
2014e
r
r3% r2%
r1%
2013
x2%
2018e
v
v3%
v2%
v1%
2017e
u
u3%
u2%
u1%
2016e
t
t3%
p2% t2%
p1%
‘000
q
q3%q 2%
q1%
2012
p t1%
2015e
s
s3% s2%
s1%
Type 1 Type 2 Type 3

6
Coronary Stents – Price Trends
Prices vary not only across stent types but also depending on whether it is indigenously manufactured or is foreign made
Type of stent
Indigenous /Foreign
Price (INR)
Remarks
Bare Metal
Indigenous
•These are price at which distributors purchase from manufacturers
•When hospitals procure stents directly from manufacturers, they can get up to ‘x’% discounts
Bare Metal
Foreign
•Price at which distributors supply the stents to hospitals
•Difficult for hospitals to procure directly from manufacturers as these stents are manufactured outside India
Drug-Eluting
Indigenous
•Price at which distributors purchase from manufacturers
•Hospitals can get discounts on these price by purchasing directly from the manufacturer
Drug-Eluting
Foreign
•Price to the end-user, that is, the patients
•Distributors can procure the lower priced, foreign made DES for as little as INR ‘a’
Bioabsorbable
Foreign
•Was priced INR ‘u’ when it was launched in Dec 2012
•Presently, Abbott has monopoly on these stents but in future as more companies produce these stents, the price is expected to fall

7
Drivers & Challenges – Summary
Drivers
Increasing lifestyle based diseases
Improving health infrastructure
Changing demographics
Increased healthcare spending and insurance coverage
Advancements in technology and medical procedures
Challenges
Problems associated with usage
Constant need for innovation and new product development

8
Regulation of medical devices such as stents are done through different divisions under the MoHFW
Organizational Structure
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6A
Level 7B
Level 6B
Level 7A
Level 7D
Level 7C

9
Although there isn’t any specific legislation governing the entire medical devices industry, certain devices are…
Regulatory Body A
•Regulatory Body A is the main body for the regulation of pharmaceuticals and medical devices in India
•Within Regulatory Body A, Entity B is responsible for the regulating pharmaceuticals and medical devices and is advised by Body C and Body D
•It is responsible for establishing the safety, efficacy, and quality standards for pharmaceuticals and medical devices
•A list of regulated pharmaceuticals and devices, Indian Pharmacopeia, is published and updated by Regulatory Body A
•It also appoints notified bodies for conducting conformity assessment procedures including tests for all drug and device applications to ensure that it complies with all standards set by the body
•Regulatory Body A is also divided into several zonal offices which conduct the pre-licensing and post-licensing inspections, post-market surveillance, and recalls whenever necessary
•Apart from the regulatory functions, Regulatory Body A also offers technical guidance and trains regulatory officials and analysts as well as monitors adverse events
•Regulatory Body A also works with the World Health Organization to promote Good Manufacturing Practice (GMP)
Regulatory Bodies (1/2)

10
Competitive Rivalry
Bargaining Power of Suppliers
Bargaining Power of Buyers
Threat of Substitutes
Threat of New Entrants
Impact
Impact
Impact
Impact
Impact
Market Competition – Porter’s Five Forces Analysis

11
Market for coronary stents in India is dominated by
products from foreign companies
Market Share – Volume-Wise (2013)
b%
a%
c%
f%
d%
h%
g%
Company 5
Company 3
Company 2
Company 4
Company 1
Company 6
Others
Competition Overview
•MNCs have a dominant share in the coronary
stents market in India
• Products from MNCs are generally viewed as
superior to those manufactured by domestic
companies
• As a result of this, there is a higher uptake of
products from foreign companies while Indian
manufacturers find it difficult to get buyers for
their products
• Company 1, company 2 and Company 3
together account for ~’m’% of the market in
terms of volume and ‘n’% of the market in
terms of value
• Company 1 is the clear leader in the market
with a a% share in volume terms in 2013
compared to p% in 2012
• Company 2 with a market share of b% had the
second-largest share

12
Key Ratios of Top 3 Companies – Operational Basis (FY 2013) (1/3)
Competitive Benchmarking – Private Companies (1/4)
0
10
20
30
40
50
a1
b2
Company 2
b1
Company 1
a2
a3
Company 3
%
b3
Operating Margin Net Margin
• Company 3 recorded operating margin of a3%, higher than that of Company 2 and Company 1 which recorded
operating margin of a2% and a1% respectively
• Net margin was highest for Company 2 which recorded a net margin of b2%, followed by Company 1 and Company 3
which recorded net margin of b1% and b3% respectively

13
Key People
Products and Services
Company Information
Offices and Centres – India
Corporate Address
Tel No.
Fax No.
Website
Year of Incorporation
Ticker Symbol
Stock Exchange
Category
Products/Services
Medical Equipment
Interventional Devices
Name
Designation
Person 1
Chairman and Managing Director
Person 2
Director
Person 3
Director
Person 4
Independent Director
Head Office
Public: Domestic Company – Company 1 (1/5)

14
Key Ratios
Financial Summary
• Company earned a net profit of INR XX mn in FY 20XX, as
compared to net profit of INR Y mn in FY 20YY
• It reported total Income of INR XX mn in FY 20XX, registering
an increase of X per cent over FY 20YY
• It earned an operating margin of X.X per cent in FY 20XX an
increase of X.X percentage points over FY 20YY
• The company reported debt to equity ratio of X.XX in FY 20XX,
an increase of X.X per cent over FY 20YY
Particulars
y-o-y change
(2013-12)
2013 2012 2011 2010
Profitability Ratios
Operating Margin
Net Margin
Profit Before Tax Margin
Return on Equity
Return on Capital Employed
Return on Working Capital
Return on Assets
Return on Fixed Assets
Cost Ratios
Operating costs (% of Sales)
Administration costs (% of
Sales)
Interest costs (% of Sales)
Liquidity Ratios
Current Ratio
Cash Ratio
Leverage Ratios
Debt to Equity Ratio
Debt to Capital Ratio
Interest Coverage Ratio
Efficiency Ratios
Fixed Asset Turnover
Asset Turnover
Current Asset Turnover
Working Capital Turnover
Capital Employed Turnover
Improved Decline
Financial Snapshot
Total Income Net Profit / Loss
6
4
2
0
25
20
15
10
5
0
INR bn INR bn
2013
a4
b4
2012
a3
b3
2011
a2
b2
2010
a1
b1
Financial Summary
Indicators Value (dd/mm/yyyy)
Market Capitalization (INR bn)
Total Enterprise Value (INR bn)
EPS (INR)
PE Ratio (Absolute)
Public: Domestic Company – Company 1
(2/5)

15
Key Business Segments Key Geographic Segments
Business Highlights
Description News
Overview
• Company 1 is a medical device company specializing in vital signs monitoring, emergency
cardiac care, vascular treatments and sensing technologies
• It has ‘n’ subsidiaries across Country 1, Country 2, Country 3 and Country 4
Network
• It markets its products in over ‘m’ countries with significant presence in Region 1, region 2
and Region 3
Design and R&D
• It has design and development facilities in City 1, Country A; City 2 and City 3, Country B;
and City 4, Country C
30,000
20,000
10,000
0
2013
c1 b1
a1
30,000
20,000
10,000
0
2013
b2
a2
Segment 1 Segment 2 Segment 3 Region 1 Region 2
Key Business Segments
data is not available for
financial years before
2013
Key Geographic
Segments data is not
available for financial
years before 2013
Public: Domestic Company – Company 1
(3/5)

16
Business Highlights
Description
News
OEM Partnerships
•Company 1 partners with leading medical companies around the world and manufactures white-label products
Manufacturing Locations
•It has 3 manufacturing units each in Country 1 and country 2 and six units in Country 3
•In Country 3 , it has two manufacturing units each at City 1 and City 2, and one each at City 3, City 4 and City 5
•In mid 2012, the company acquired ‘k’ acres of land from the Organization A at the industrial growth centre in City 5 to set up a greenfield manufacturing facility with an investment of INR ‘p’ bn
•Three group companies of Company 1 will have their manufacturing facility here and they were expected to be ready by the end of 2013
Coronary Stents Products
•Coronary stents from the company are manufactured by Company A which is a wholly- owned subsidiary of Company B and is part of the Company 1 group
•Stainless steel and cobalt chromium bare metal stents from the company include the ‘Model 1’, ‘Model 2’, ‘Model 3’ and ‘Model 4’ stents
•It also markets ‘Model 5’ series of polymer-free DES which are coated with Paclitaxel and are available on stainless steel and cobalt chromium platforms
•‘Model 6’ coronary stent system is the company’s latest cobalt chromium coronary stent technology from the ‘Y’ series and is delivered by the company’s Paclitaxel-eluting coronary balloon dilatation catheter ‘Model A’
Public: Domestic Company – Company 1 (4/5)

17
T
O
W
S
Public: Domestic Company – Company 1 – SWOT Analysis (5/5)

18
Key People
Company Information
Offices and Centres – India
Corporate Address
Tel No.
Fax No.
Website
Products/Services
es
Name
Designation
Person 1
Director
Person 2
Director
Person 3
Director
Head Office
Private: Foreign Company – Company 2 (1/5)

19
Name
No. of Shares held
Shareholder 1
Shareholder 2
Total
100.00%
Category 1
Shareholders of the Company as on dd/mm/yy
Ownership Structure

20
Financial Snapshot Key Ratios
Financial Summary
• Company earned a net profit of INR XX mn in FY 20XX, as
compared to net profit of INR Y mn in FY 20YY
• It reported total Income of INR XX mn in FY 20XX, registering
an increase of X per cent over FY 20YY
• It earned an operating margin of X.X per cent in FY 20XX an
increase of X.X percentage points over FY 20YY
• The company reported debt to equity ratio of X.XX in FY 20XX,
an increase of X.X per cent over FY 20YY
Improved Decline
Total Income Net Profit / Loss
5
-15
0
-5
-10
-20
-25
30
25
20
15
10
5
0
INR bn INR bn
2013
a4
b4
2012
a3
b3
2011
a2
b2
2010
a1
b1
Particulars
y-o-y change
(2013-12)
2013 2012 2011 2010
Profitability Ratios
Operating Margin
Net Margin
Profit Before Tax Margin
Return on Equity
Return on Capital Employed
Return on Working Capital
Return on Assets
Return on Fixed Assets
Cost Ratios
Operating costs (% of Sales)
Administration costs (% of
Sales)
Interest costs (% of Sales)
Liquidity Ratios
Current Ratio
Cash Ratio
Leverage Ratios
Debt to Equity Ratio
Debt to Capital Ratio
Interest Coverage Ratio
Efficiency Ratios
Fixed Asset Turnover
Asset Turnover
Current Asset Turnover
Working Capital Turnover
Capital Employed Turnover
Note: Financial year ending 31st Dec
Private: Foreign Company – Company 2
(3/5)

21
Business Highlights
Description
News
Overview
•Company 2 operates in the nutritional products, laboratory diagnostics, medical devices, and pharmaceutical therapies space
•It was previously the domestic formulations business of Company A and was renamed as Company 2 after it was acquired by Company B in May 2010
Manufacturing Facility
•It has a formulation facility at City 1, State 1 where a wide range of formulations and dosage forms are manufactured
•However, coronary stents sold by the company in India are manufactured by various subsidiaries of the parent company Company B
Coronary Stents Products
•A number of models of coronary stents from the company are available in India
•‘Model 1’ Carotid Stent System and ‘Model 2’ Coronary Stent marketed by the company are manufactured by Company C, Country 1
•‘Model 3’ Coronary Stent System and ‘Model 4’ series are manufactured by Company D, Country 2
•‘Model 5’ Stent System is manufactured by Company E in its manufacturing facility at City 3, Country 3
•Everolimus Eluting ‘Model 6’, ‘Model 7’, ‘Model 8’, ‘Model 9’, ‘Model 10’ and ‘Model 11’ are manufactured by Company F, Country 4
•‘Model 12’ stent system are manufactured by Company G, Country 5
•In 20xx, ‘Model 13’, a Type A stent from the company, was launched in India at a price of INR ‘y’ mn; however the price was decreased to INR ‘z’ mn within 6 months due to the overwhelming response that it received

22
T
O
W
S
Private: Foreign Company – Company 2 – SWOT Analysis (4/5)

23
Hospital Name
Hospital Logo
Hospital Chain
Ownership Type
Angioplasty Procedures Per Month
All India Institute of Medical Sciences
Max Super Specialty Hospital
Asian Heart Institute
B.M. Birla Heart Research Centre
Apollo Hospital#
Sri Jayadeva Institute of Cardiology
Narayana Hrudayalaya
Fortis Healthcare*
Wockhardt Hospital**
Metro Heart Institute
Top 10 hospitals buying coronary stents in India
Buyer Snapshot: List of Top 10 Buyers of Coronary Stents

24
Key People
Company Information
Corporate Address
Tel No.
Fax No.
Website
Name
Designation
Person 1
President (Institute Body)
Person 2
Dean
Person 3
Director
Person 4
Medical Superintendent
Category
Products/Services
Specialty Centers
Surgery
Laboratory
Head Office and Hospital Network– India
Public: Domestic Company – Hospital 1 (1/3)
Head Office
Hospital Network

25
Description
News
Overview
•Hospital 1 is a group of 7 hospitals across India
•It has ‘m’ teaching departments and centers, a total of ‘p’ beds, ‘q’ doctors (including faculty members, senior and junior residents) and ‘r’ nurses
Facilities
•It is a leader in stem cell therapy, especially in the fields of cardiology and neurology
•It has India's first and only minimally invasive surgery training centre, under collaboration with Germany
•It is a pioneer of robotic surgeries in India, particularly the Da Vinci system for urology, and robotic CTVS
•The first in-vitro fertilization facility in the public sector was set up at the Hospital in Feb 2008
Future Plans
•Expansion plans of the hospital were recently approved by the Regulatory Body A
•The government is planning to set up two more such hospitals cum institutions at City 1, State 1 and City 2, State 2
Business Highlights

26
Parameter
Hospital Indicators
Total cardiac patients per month
Angioplasties per month
Stent providers
Purchase decision factors
Stents procurement
Centralized/ Hospital level
Contact details
HOD/ Technician/ Procurement
Procedure/ process involved in procurement
Contact details – Purchase
Stent types
Overview of Stent Procurement Process

27
Thank you for the attention
About Netscribes, Inc.
Netscribes, Inc. is a knowledge-consulting and solutions firm with clientele across the globe. The company’s expertise spans areas of investment & business research, business & corporate intelligence, content-management services, and knowledge-software services. At its core lies a true value proposition that draws upon a vast knowledge base. Netscribes, Inc. is a one-stop shop designed to fulfil clients’ profitability and growth objectives.
Coronary Stents Market – India report is part of Netscribes’ Healthcare Series.
For any queries or customized research requirements, contact us at:
Disclaimer: This report is published for general information only. Although high standards have been used in the preparation, “Netscribes” is not responsible for any loss or damage arising from use of this document. This document is the sole property of Netscribes and prior permission is required for guidelines on reproduction.
Phone: +91 22 4098 7600
E-Mail: info@netscribes.com

Market Research Report : Coronary stents market in india 2014 - Sample

Recomendados

Recomendados

Más contenido relacionado

La actualidad más candente

La actualidad más candente (20)

Destacado

Destacado (13)

Similar a Market Research Report : Coronary stents market in india 2014 - Sample

Similar a Market Research Report : Coronary stents market in india 2014 - Sample (20)

Más de Netscribes, Inc.

Más de Netscribes, Inc. (20)

Último

Último (20)

Market Research Report : Coronary stents market in india 2014 - Sample